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Abstract  
Background and purpose 
The 5-HT3 receptor is a prototypical member of the Cys-loop ligand-gated ion 
channel (LGIC) superfamily and an established therapeutic target. In addition to 
activation via the orthosteric site, receptor function can be modulated by allosteric 
ligands. We have investigated the pharmacological action of Cl-indole upon the 5-
HT3A receptor and identified that this positive allosteric modulator possesses a novel 
mechanism of action for LGICs.  
Experimental approach 
The impact of Cl-indole upon the 5-HT3 receptor was assessed using single cell 
electrophysiological recordings and [3H]granisetron binding with HEK293 cells stably 
expressing the 5-HT3 receptor.  
Key results 
Cl-indole failed to evoke 5-HT3A receptor mediated responses (up to 30 µM) or 
display affinity for the [3H]granisetron binding site. However, in the presence of Cl-
indole, termination of 5-HT application revealed tail currents mediated via the 5-HT3A 
receptor that were independent of the preceding 5-HT concentration but were 
antagonised by the 5-HT3 receptor antagonist, ondansetron. These tail currents were 
absent in the 5-HT3AB receptor. Furthermore, the presence of 5-HT revealed a 
concentration-dependent increase in the affinity of Cl-indole for the orthosteric 
binding site of the h5-HT3A receptor.  
Conclusions and implications 
Cl-indole acts as both an orthosteric agonist and an allosteric modulator but the 
presence of an orthosteric agonist (e.g. 5-HT) is a prerequisite to reveal both actions. 
Precedent for ago-allosteric action is available yet the essential additional presence 
of an orthosteric agonist is now reported for the first time. This widening of the 
pharmacological mechanisms to modulate LGICs may offer further therapeutic 
opportunities.  
Tables of Links 
Targets 
5-HT3 Receptorsa 
5-HT3A 
5-HT3AB 
 
Ligands 
[3H]-granisetron: IUPAC name 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-7-
yl)indazole-3-carboxamide 
5-hydroxytryptamine: IUPAC name 3-(2-Aminoethyl)-1H-indol-5-ol 
5-methylindole: IUPAC name 5-methyl-1H-indole. Not found in ligand database 
5-hydroxyindole: IUPAC name 1H-Indol-5-ol 
5-chloroindole: IUPAC name 5-chloro-1H-indole. Not found in ligand database 
Ondansetron: IUPAC name 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-
1H-carbazol-4-one 
Phenylbiguanide: IUPAC name 1-(diaminomethylidene)-2-phenylguanidine 
These Tables of Links list key protein targets and ligands in this article that are hyperlinked 
to corresponding entries in http://www.guidetopharmacology.org, the common portal for 
data from the IUPHAR/BPS Guide to Pharmacology (Southan et al., 2016), and are 
permanently archived in The Concise Guide to Pharmacology 2015/16 (aAlexander et al., 
2015) 
 
 
Abbreviations 
Cl-indole: 5-chloroindole; LGIC: ligand-gated ion channel; nAChR: nicotinic 
acetylcholine receptor; COM: cryptic orthosteric modulator; 5-HT: 5-
hydroxytryptamine; 5OHI: 5-hydroxyindole; 5MeI: 5-methoxyindole 
  
Introduction 
The 5-HT3 receptor is an excitatory ligand-gated ion channel (LGIC) of the Cys-loop 
family that includes the nicotinic acetylcholine receptors (nAChR), glycine and 
GABAA receptors, and Zn2+-activated receptors (Barnes et al., 2009; daCosta et al., 
2013). Members of this LGIC family share a common pentameric structure, an 
observation recently confirmed by the publication of the X-ray structure of the mouse 
5-HT3A receptor (Hassaine et al., 2014). Each subunit of the 5-HT3 receptor is 
composed of an extracellular N-terminal domain, four transmembrane domains and 
a short extracellular C-terminal domain. The orthosteric binding site is located at the 
interface between two adjacent N-terminal domains (daCosta et al., 2013). 
 
Five human 5-HT3 receptor subunits have been identified (5-HT3A to 5-HT3E) 
(Karnovsky et al., 2003; Niesler et al., 2003). The native receptor can exist as a 
simple homopentamer of 5-HT3A subunits or heteropentamers containing the 5-
HT3A subunit and at least one other of the 5-HT3B to E subunits (Niesler, 2011). 
The pentameric structure gives rise to a potential for five ligand binding sites but 
recent evidence suggests that just two or three sites are occupied for maximal 
activation of the channel (Corradi et al., 2009). Studies using heteromeric 5-HT3AB 
receptors suggest that orthosteric binding sites are only formed between adjacent 5-
HT3A subunits (Lochner et al., 2010; Thompson et al., 2011). 
 
As well as orthosteric agonism, allosteric modulation of the 5-HT3 receptor has been 
reported by compounds as diverse as alcohols (Bentley et al., 1998; Downie et al., 
1995; Stevens et al., 2005), cannabinoids (Barann et al., 2002), indole derivatives 
(Newman et al., 2013; Parker et al., 1996; Van Hooft et al., 1997), terpenes (Lansdell 
et al., 2015; Ziemba et al., 2015), benzamides (Jørgensen et al., 2011) and the class 
of novel negative allosteric modulators typified by PU02 (Trattnig et al., 2012). A 
number of these modulators appear to have their effect via a site (or sites) in the 
transmembrane domain (e.g. for the indole derivatives (Hu et al., 2008)). Allosteric 
agonism by phenolic monoterpenes has also been reported recently again via an 
allosteric transmembrane site (Lansdell et al., 2015). An additional potential level of 
allosteric modulation has been demonstrated since mutation of the intracellular portal 
region of the receptor affected gating and co-operativity (e.g. (Kozuska et al., 2014)). 
This raises the possibility of receptor interactions with intracellular proteins leading to 
allosteric modulation of receptor function. 
 
Whilst the majority of these allosteric effects are mediated by discrete, non-
orthosteric sites, it is becoming apparent that some indole derivatives have a more 
intriguing and mixed mode of action. In particular, they may have mixed effects 
depending on their concentration and structure. For instance, the non-selective 
positive allosteric modulator, 5-hydroxy-indole (5OHI) displays positive allosteric 
modulation via a transmembrane domain of mouse 5-HT3A receptors (Hu et al., 
2008), and can also display orthosteric agonism and allosteric inverse agonism at a 
spontaneously active mutated mouse 5-HT3A receptor. These differing actions were 
dependent only on concentration. The closely related molecule, 5-methoxy-indole 
(5MeI) displayed both allosteric agonism and orthosteric inverse agonism at the 
same receptor, again dependent on concentration (Hu, 2015).  Importantly the 
presence of the orthosteric ligand was not required for these actions. 
 
We have recently described a selective allosteric modulator of the 5-HT3 receptor, 5-
chloro-indole (Cl-indole; (Newman et al., 2013). Our study suggested that Cl-indole 
slows the decay of 5-HT3A receptor currents and that it can reactivate desensitised 
5-HT3A receptors in the continued presence of 5-HT (Newman et al., 2013). In the 
light of the mixed modes of action described for indole derivatives, we undertook a 
study to further explore the mode of action of Cl-indole on the modulation of the 5-
HT3 receptor. We identified for the first time within the LGIC superfamily, an ago-
allosteric modulation in which both agonism and allosteric modulation require the 
presence of the orthosteric ligand. 
 
 
  
 Materials and Methods 
Nomenclature 
The molecular target nomenclature conforms to the British Journal of 
Pharmacology’s Concise Guide to Pharmacology (Alexander et al., 2015). 
 
Cell Culture 
HEK293 cells stably expressing the human 5-HT3A subunit (HEK293-5-HT3A cells 
(Brady et al., 2001)) or the heteromeric 5-HT3A/5-HT3B receptor (HEK293-5-
HT3A/3B cells) (Dubin et al., 1999) were grown in Dulbecco’s Modified Eagle’s 
Medium, supplemented with 10% (v/v) foetal bovine serum, 1% (v/v) 
penicillin/streptomycin (10,000 U ml-1 penicillin and 10 mg ml-1 streptomycin) and 
G418 (250 μg ml-1)  or G418 plus zeocin (250 g ml-1 each, HEK293-5-HT3A/3B 
cells) and maintained at 37°C, 5% CO2, 95% air at 95% relative humidity.  
 
Radioligand binding 
Radioligand binding assays were performed similar to our previous studies (e.g. 
(Monk et al., 2004)). Briefly, cells were homogenised (Polytron) and resuspended in 
Tris buffer (in mM; Tris 25, pH 7.4 adjusted with NaOH). Radioligand binding assays 
were performed in triplicate; binding tubes contained 500 µl of competing drug(s) or 
vehicle (Tris buffer), and 100 µl of [3H]-granisetron (1 nM); 3 TBqmmol-1; Perkin-
Elmer). An aliquot (100 µl) of the cell homogenate was added to initiate binding, 
which was allowed to proceed at room temperature for 60 min before termination by 
rapid filtration and washing with Tris buffer under vacuum through Whatman GF/B 
filters, followed by assay of the radioactivity remaining on the filters.  
5HT-Binding Protein 
The A1B2D1W 5HT-binding protein was produced and binding experiments with the 
protein were performed exactly as described by (Kesters et al., 2013). Radioactivity 
was determined using a Top Count Scintillation and Luminescence reader (Packard). 
Single cell electrophysiology 
Approximately 18h prior to electrophysiology assays, cells were seeded directly onto 
13 mm diameter glass coverslips coated with poly-L-lysine and fibronectin, at a 
density of 2 x 104 cells per coverslip. Macroscopic currents were recorded in the 
whole-cell recording mode of the patch-clamp technique from HEK293-5-HT3A cells 
or HEK293-5-HT3A/3B cells cultured on coverslips using an inverted microscope. 
Cells were superfused at ~4 ml min-1 with an extracellular solution (in mM; NaCl 140, 
KCl 2.8, CaCl2 1.0, glucose 10, HEPES 10, pH 7.4 adjusted with NaOH). Patch 
electrodes were pulled from borosilicate glass (O.D. 1.2 mm, I.D. 0.69 mm; Harvard 
Apparatus, Edenbridge, UK) using a P-97 puller (Sutter, Novato, CA) and filled with 
intracellular solution consisting of (in mM) 135 CsCl, 2 MgCl2, 10 HEPES, 1 EGTA, 2 
Mg-ATP and 0.3 Na-GTP; pH adjusted to 7.3 with KOH (osmolarity ~285 mOsm). 
Patch electrodes typically had open tip resistances of 4-7 MΩ. Membrane currents 
were recorded using an Axopatch 200B amplifier (Molecular Devices, Wokingham, 
UK), low-pass Bessel filtered at 1 kHz (NL-125, Digitimer Ltd, Welwyn Garden City, 
UK) and digitized at 10 kHz by a digidata 1302 (Molecular Devices). Experiments 
were performed at room temperature with the cells voltage-clamped at -60 mV.  
 
Agonist-evoked currents were elicited by pressure ejection (20-kPa; Picospritzer II; 
General Valve, Fairfield, NJ) of agonist (5-HT 1.0-10 µM) from modified patch 
pipettes placed ~30 µm from the recorded cell. 
 
Data and Statistical Analysis 
Values are expressed as mean±SEM. Curve fitting and data analysis were 
performed in Origin 8 (Silverdale Scientific, Stoke Mandeville, UK). Experimenters 
were not blinded to the experimental conditions.  Experiments were randomised 
where appropriate (eg for the paired pulse experiments, interpulse interval was 
randomised using a latin square design). ANOVA with subsequent unpaired t-tests 
(with Bonferonni correction for multiple comparisons) were used to evaluate 
differences; a Shapiro-Wilk tested normality. Post-hoc tests were only conducted if F 
was <0.05; the variance of the data was homogenous.  Significance criterion was 
p<0.05. 
Data and statistical analysis complied with the recommendations on experimental 
design and analysis in pharmacology (Curtis et al., 2015). 
  
Results 
Cl-Indole modulates 5-HT-induced responses but is not an agonist 
A brief application of Cl-indole (30 M, 100 ms) did not evoke a current in HEK293 
cells expressing the human 5-HT3A receptor (Figure 1) whereas bath application of 
5-HT (10 M) produced a large inward current. As the 5-HT-induced current began 
to decay, a second brief application of Cl-indole (30 M, 100 ms) reactivated the 
current (Figure 1). These data demonstrate the Cl-indole is not an agonist in its own 
right, but in the presence of 5-HT, it is capable of modulation of the 5-HT3A receptor. 
The reactivation of the current suggested that Cl-indole might act via an effect on 
either desensitisation or resensitisation of the receptor. 
 
Cl-Indole does not modulate 5-HT3A receptor desensitisation 
In order to establish if Cl-indole modulates receptor desensitisation, we tested the 
effect of Cl-indole on the rate of receptor desensitisation evoked by prolonged 
receptor activation. Twenty second applications of 5-HT (10 μM) produced large 
currents (1.53±0.25 nA, n=11) that displayed profound desensitisation (12.4±3.23% 
of peak; Figure 2Ai).  The current decay was best fit with a double exponential 
function, with time constants of 1.02±0.09 s and 9.79±1.09 s (Figure 2Bi & Bii). 
Superfusion of Cl-indole (10 μM) did not alter the amplitude of 5-HT induced currents 
(1.37±0.27 nA, n=11, p=0.54); nor did it alter the degree (13.9±3.9 % of peak, 
p=0.79) or rate (1 1.22±0.20 s, p=0.31; 2 7.78±0.41 s, p=0.21) of receptor 
desensitisation (Figure 2Biii). These data demonstrate that Cl-indole does not 
modulate 5-HT3A receptor desensitisation. 
 
Cl-indole does not modulate 5-HT3A receptor resensitisation 
We previously demonstrated that when 5-HT3A receptors were completely 
desensitised by prolonged application of 5-HT, subsequent application of Cl-indole 
generated an inward current indicative of Cl-indole being able to reactivate 
desensitised receptors (Newman et al., 2013) (see also Figure 1).  We therefore 
tested whether Cl-indole could modulate receptor resensitisation using a dual pulse 
protocol; a single prolonged application of 5-HT (10 μM, 20 s) induced receptor 
desensitisation (Figure 3A). After removal of the 5-HT, a second test pulse of 5-HT 
(10 μM, 1 s) was applied with a delay between 5 s and 2 minutes. Recovery from 
desensitisation was estimated by the fractional recovery of the current elicited by the 
second 5-HT pulse and was plotted against the inter-pulse interval.  Cl-indole did not 
modulate the rate of receptor resensitisation (control r=18.4±2.0 s; Cl-indole r 
17.7±3.1 s; n=5, p=0.8; Figure 3B). 
 
Cl-indole induces tail currents 
In the absence of Cl-indole, removal of 5-HT resulted in the evoked currents 
decaying back to the resting holding current level (see Figure 3A and 4A, black 
traces). In contrast, removal of 5-HT in the continued presence of Cl-indole resulted 
in a relatively large, slowly developing inward tail current which peaked at 
158.3±30.1 pA (13.3±1.8%) of the 5-HT-induced current amplitude (Figure 4A, red 
trace; n=13; see also Figure 3A, red trace).  The rise time of the tail current was best 
fit by a single time constant ( 2.77±0.35 s) and the tail current decayed slowly back 
to baseline (time to reach 50% level 11.06±1.7 s).  The effect of Cl-indole on the 
presence of a tail current was completely reversed upon wash (Figure 4A, grey 
trace). As the tail current arose immediately after the removal of the 5-HT, we 
examined if the tail current amplitude was correlated with the current remaining at 
the end of the agonist application; we also used lower concentrations of 5-HT (1 - 3 
µM and 1 µM) as these lower 5-HT concentrations evoked currents with reduced 
desensitisation (Figure 4B). The tail current amplitude did not correlate with the 
amount of current remaining (Figure 4Bi, n=27, ANOVA p=0.32).  In contrast, the 
amplitude of the tail current correlated positively with the 5-HT3A receptor current 
density (Figure 4Bii, n=13, ANOVA p<0.001). 
In order to further explore the origin of the tail current, we examined the current-
voltage relationship of the tail current.  Similar to the IV curve for the 5-HT3A receptor 
current, the IV curve for the tail current reversed at approximately zero mV (Figure 
5).  These data suggest that the tail current arises from activation of 5-HT3A 
channels (see also figure 7), and that channel opens in a manner consistent with 
orthosteric receptor activation. 
The tail current recorded in the presence of Cl-indole was qualitatively similar to tail 
currents that arise following relief from open channel block (Rossokhin et al., 2014).  
Given that 5-HT is known to induce channel block at concentrations above 5 µM 
(Corradi et al., 2009), we explored further if Cl-indole could induce tail currents after 
application of lower concentrations of 5-HT.  Cl-indole did not potentiate 3 µM 5-HT-
induced currents (Control = 0.73±0.11 nA; Cl-indole = 0.68±0.17 nA; n=6, p=0.91), 
yet the presence of Cl-indole induced a tail current upon removal of the lower 
concentration of 5-HT (Figure 6).  Following removal of 5-HT at 3 µM, the tail current 
peaked at 135±29.8 pA (18.7±3.3 % of the agonist induced current; n=6, p=0.15), 
with a similar decay time (8.54±1.1 s; p=0.65).  The rise time in the tail current 
(5.42±0.78 s) following removal of 5-HT at 3 µM was significantly slower than for tail 
currents evoked following removal of 10 µM 5-HT (p=0.01, Figure 6). 
Cl-indole (10 µM) potentiated 1.0 µM 5-HT-induced currents (Control = 149.0±50.7 
pA; Cl-indole = 473.5±146.0 pA; n=9, p=0.03) but not currents arising from higher 
concentrations of 5-HT. In the presence of Cl-indole (10 µM), tail currents were also 
observed following removal of 5-HT at 1 µM; the peak amplitude of the tail current 
was 197.5±50.6 pA, the rise time was significantly slower (7.37±0.81 s; p<0.001) and 
the decay time was unaltered (13.73±1.0 s; n=9, p=0.26; Figure 6).  Although the 
peak amplitude of the tail current evoked by removal of 1 M 5-HT did not 
significantly differ from those evident following removal of higher 5-HT 
concentrations, the Cl-indole-induced tail currents evoked following removal of 1 µM 
5-HT were significantly larger relative to the 5-HT-induced peak current (108.2±37.3 
%; n=9, p=0.003). 
 
Does Cl-indole function as an ago-allosteric modulator?  
The homomeric 5-HT3A receptor has 5 potential orthosteric binding sites, but various 
studies have shown that even when fully activated only 3 molecules of 5-HT are 
bound per receptor leaving unbound orthosteric sites (Corradi et al., 2009; Mott et 
al., 2001; Solt et al., 2007). Given the structural similarity between Cl-indole and the 
natural ligand 5-HT, we hypothesised that Cl-indole may function as an ago-allosteric 
modulator, a mode of action which has previously been described in members of the 
GPCR superfamily (Schwartz et al., 2006).  We tested this in two ways: firstly, we 
examined if the competitive antagonist, ondansetron, which interacts with the 
orthosteric site, could block the Cl-indole-induced tail current.  Secondly, we 
examined if 5-HT could modulate the ability of Cl-indole to interact with the 
orthosteric site in radioligand binding studies. 
In the continual presence of Cl-indole, ondansetron (10 µM) was applied via a 
second picospritz pipette one second prior to the withdrawal of the 5-HT.  In the 
absence of ondansetron, tail current amplitude was 250±18 pA, whereas effectively 
no tail current was observed in the presence of ondansetron (11±3 pA; n= 5, 
p<0.001 Figure 7A).  In a parallel set of experiments, we tested the effect of 
ondansetron (10 µM) applied after development of the tail current. Ondansetron 
applied at the peak of the tail current immediately reduced the current back to 
baseline levels (Figure 7B, n=5). The duration of the tail current (in the order of 
seconds) would suggest that it is occurring without the presence of the orthosteric 
ligand (which would be washed away).  As ondansetron copmpetively binds at the 
orthosteric site (Duffy et al., 2012) this strongly argues that Cl-indole interacts with 
the orthosteric site. 
These data demonstrate that antagonism of the orthosteric site prevents Cl-indole-
evoked tail currents.   
We have previously demonstrated that Cl-indole (in the absence of 5-HT) at 
concentrations up to 100 µM does not compete with [3H]-granisetron binding at the 
5-HT3A receptor (Newman et al., 2013), which was confirmed in the present study 
(Figure 8).  However, in the presence of sub-maximal concentrations of 5-HT, Cl-
indole competed for [3H]-granisetron binding sites, with the affinity of Cl-indole 
increasing for the [3H]-granisetron-labelled orthosteric site of the 5-HT3A receptor 
binding site with increasing concentrations of 5-HT (Figure 8, Table 1). In contrast, 
parallel experiments demonstrated that sub-maximal concentrations of 5-HT failed to 
modify the affinity of the partial agonist phenylbiguanide (Figure 8, Table 1). 
In complementary experiments we tested the ability of Cl-indole to bind to the 5-HT 
binding protein. This protein, formed by mutation of the acetylcholine binding protein, 
is able to bind 5-HT albeit with reduced affinity compared to the native 5-HT3 
receptor (Kesters et al., 2013). At higher concentrations, Cl-indole competed with 
[3H]-granisetron but did not show the same increase in affinity in the presence of 5-
HT as for the homomeric receptor (supplementary data figure 1), which suggests the 
5-HTBP does not fully replicate the interaction of Cl-indole with the h5-HT3A 
receptor. 
 
Cl-indole does not induce tail currents in the heteromeric 5-HT3AB receptor 
In contrast to the 5-HT3A receptor, the heteromeric 5-HT3AB receptor has been 
reported to have only one orthosteric site, formed at the interface of two A subunits 
(Miles et al., 2013). Since the action of Cl-indole requires the presence of the 
orthosteric agonist, we hypothesised that the agonist activity of Cl-indole would not 
be apparent at the heteromeric receptor. Unlike the homomeric receptor, the 
presence of Cl-indole (10 M) did not induce a tail current after removal of 5-HT; it 
did however potentiate the peak current amplitude (control 786.7±108.3 pA, Cl-
indole 1111.9±192.5 pA, n=6, p=0.03, Figure 9B). As subtle differences exist in the 
pharmacology of the heteromeric receptor, we tested if a higher concentration of Cl-
indole (30 M) would induce tail currents. Cl-indole did not induce a tail current but 
did again potentiate the peak current amplitude (control 585.1±56.2 pA, Cl-indole 
984.4±136.5 pA, n=5, p=0.02, Figure 9A, B).  Consistent with the lack of tail current 
in the heteromeric receptor, the presence of submaximal concentrations of 5-HT did 
not modulate the affinity of Cl-indole binding at the 5-HT3AB receptor (Table 2). 
 
  
Discussion 
Our previous studies demonstrated that Cl-indole was a potent and selective positive 
allosteric modulator of the 5-HT3 receptor (Newman et al., 2013).  Cl-indole slowed 
the rate at which 5-HT3A receptor-mediated currents decayed back to baseline 
following a brief application of 5-HT and appeared able to reactivate desensitised 
receptors (Newman et al., 2013). In the present study we demonstrated that Cl-
indole alone fails to activate the 5-HT3A receptor, although the presence of 5-HT 
reveals an action of Cl-indole once desensitisation had commenced (Figure 1). 
Based on the present and our previous studies, we therefore hypothesised that Cl-
indole may modulate the desensitised state of the receptor.  In the present studies 
the mechanism of action of Cl-indole was explored more fully. We used prolonged 
applications of the endogenous orthosteric agonist, 5-HT, to induce robust 
desensitisation of the 5-HT3A receptor but Cl-indole did not alter either the rate or 
magnitude of receptor desensitisation (Figure 2Biii) or the rate at which 5-HT3A 
receptors recovered following desensitisation (Figure 3). Given that some other 
allosteric modulators of 5-HT3A receptors have a profound effect on desensitisation 
rate (Deiml et al., 2004; Kooyman et al., 1993; Van Hooft et al., 1997), our data 
suggest that Cl-indole functions via an alternate mechanism.  
A surprising observation from the desensitisation studies was that the presence of 
Cl-indole revealed tail currents following removal of the 5-HT. Our unpublished data 
show that mutation of the 5OHI binding site in the human 5-HT3A receptor used in 
this study, had no effect on the ability of Cl-indole to modulate the 5-HT response.  A 
tail current has previously been described following the treatment of mouse 5-HT3A 
receptors with 5OHI (Kooyman et al., 1993). High concentrations of 5OHI (10 to 50 
mM) evoked a tail current superficially similar to that evoked by Cl-indole in our 
study. However unlike Cl-indole, high concentrations of 5OHI inhibited the 5-HT 
response and the tail currents could be ascribed to relief of 5OHI-mediated block. 
Similarly, 10 mM trichloroethanol also induced a tail current at mouse 5-HT3A 
receptors, which was ascribed to relief from a blocked state (Zhou et al., 1996). 
Indeed, tail currents are most commonly ascribed to the relief from non-competitive 
open channel block. For example, penicillin is an open-channel blocker at the 
GABAA receptor, where it binds within the pore and locks the receptor into an open 
but blocked conformation (Rossokhin et al., 2014). Removal of penicillin generates 
large tail-currents as receptors transition from an open-blocked to an open, ion-
permeant state (Rossokhin et al., 2014). Open channel block of the 5-HT3A receptor 
by 5-HT has been described by Hapfelmeier et al (Hapfelmeier et al., 2003) in 
macroscopic currents and at the single channel level by Corradi et al (Corradi et al., 
2009).  It has been proposed that 5-HT can occupy a non-agonist binding site and 
block conductance through the receptor in an open-channel like manner. It is 
therefore possible that Cl-indole may enhance 5-HT-mediated open-channel block, 
thereby causing a larger proportion of receptors to exist in a blocked state during 
continued agonist exposure. Following agonist removal, this population of receptors 
would transition from blocked to the open-conductive state and produce the 
observed tail currents. However, our data indicates that Cl-indole does not function 
in this manner. Previous reports of 5-HT-mediated channel block have shown that it 
is only evident at concentrations exceeding 5 μM (Corradi et al., 2009; Hapfelmeier 
et al., 2003). In the present studies tail currents were associated with lower 
concentrations of 5-HT, the amplitude of tail currents was not altered across the 
range of 5-HT concentrations investigated (1-10 μM), and tail currents were not 
observed in the absence of Cl-indole. Taken together, these data indicate that Cl-
indole-induced tail currents do not arise from promotion of channel block. 
We propose that Cl-indole potentiates 5-HT mediated responses by a novel 
mechanism where in the presence of the orthosteric ligand (5-HT), Cl-indole can 
bind to orthosteric sites leading to increased receptor activity.  Several observations 
support this hypothesis: (1) the concentration-dependent presence of 5-HT reveals 
an ability of Cl-indole to compete for the [3H]granisetron-labelled orthosteric binding, 
(2) the orthosteric 5-HT3 receptor antagonist, ondansetron, effectively blocks the Cl-
indole-dependent tail current and (3) the IV curve of the tail current is 
indistinguishable from that for the 5-HT3A receptor. Additional support is lent by the 
observation that in a heteromeric 5-HT3AB receptor with potentially only one 
available orthosteric site, no tail current was observed. Our interpretation is therefore 
that Cl-indole acts as both a positive allosteric modulator and an orthosteric agonist 
requiring the presence of an orthosteric ligand such as 5-HT.  
Ago-allosteric modulators have been defined as ligands that can function both as an 
agonist in their own right and as an allosteric modulator of the orthosteric ligand 
(Schwartz et al., 2007). This class of modulators has been well described for GPCRs 
(Smith et al., 2011a; Smith et al., 2011b; Yamazaki et al., 2012) but has also been 
described for cys-loop LGICs. Thus phenobarbitol, 4BP-TQS and thymol and 
carvacrol have all been described as ago-allosteric modulators for GABAA, nicotinic 
7 and 5-HT3A receptors, respectively (Amin et al., 1993; Gill et al., 2011; Lansdell 
et al., 2015). However, all these modulators act as allosteric agonists in the absence 
of the orthosteric ligand. Interestingly, 4BP-TQS acts via a site in the TM2 domain of 
the nicotinic 7 receptor (Gill et al., 2011), while thymol and carvacrol display 
agonism via a site in TM1 of the 5-HT3A receptor (Lansdell et al., 2005).  
The proposed mechanism of action of Cl-Indole shows some similarity to compounds 
that modulate nAChRs by acting through ‘non-canonical’ extracellular agonist 
binding sites (Short et al., 2015) or as ‘accessory site-selective agonists’ (Wang et 
al., 2015). These compounds act at heteromeric receptors with the mechanism of 
action explained by compounds interacting with sites distinct from the conventional 
orthosteric site.  Importantly, this study examined the effect of Cl-Indole on 
homomeric 5-HT3A receptors, which are expected to have five identical agonist 
binding sites. 
Therefore Cl-indole fundamentally differs from previously described modulators by its 
agonist action at the orthosteric site, as well as its allosteric action, both of which 
require the additional presence of an orthosteric ligand such as 5-HT.  Since the 
action of Cl-indole is hidden, requiring the presence of an orthosteric agonist to be 
revealed, we propose that it forms a new class of action that we term cryptic 
orthosteric modulation (COM). 
The 5-HT3A receptor has five orthosteric sites (Barnes et al., 2009) of which two to 
three are believed to be occupied for maximal receptor activation (Corradi et al., 
2009). The question therefore arises whether Cl-indole binds to unoccupied 
orthosteric sites or does it compete with 5-HT for occupied sites?  Both in this study 
and previously (Newman et al., 2013) we have shown that Cl-indole potentiates 
responses induced by sub-maximal but not maximal 5-HT concentrations.  Studies 
investigating receptor stoichiometry using nAChR suggest that agonist binding to a 
single binding site within the LGIC complex can activate the channel (Andersen et 
al., 2013; Rayes et al., 2009).  As the number of binding sites engaged increases, 
the channel can become maximally activated (Corradi et al., 2009). Therefore at low 
agonist concentrations it would be predicted that relatively few binding sites are 
occupied and the current amplitude is consequently lower.  Cl-indole can then 
interact with the free orthosteric sites to potentiate the response; this action is only 
revealed by the presence of 5-HT.  In contrast at higher 5-HT concentrations, 
multiple orthosteric binding sites are occupied, effectively blocking Cl-indole access 
to the orthosteric site.  As a result Cl-indole cannot potentiate the response. Once 
the 5-HT molecules begin to dissociate, the orthosteric binding sites become 
sequentially available, allowing Cl-indole to bind and re-activate the channel, thus 
generating the evident tail current.  This proposes that Cl-indole can only interact 
with unoccupied orthosteric sites. Our previous study demonstrated that when Cl-
indole was applied to desensitised receptors, a current was evoked (Newman et al., 
2013), which in the light of the present findings suggests that this current may have 
resulted from generation of a tail current. 
The heteromeric 5-HT3AB receptor has been reported to have the subunit order of A-
A-B-A-B ((Miles et al., 2013) Since the orthosteric site is formed from an A-A 
interface, this stoichiometry suggests the presence of just a single orthosteric site in 
the heteromeric 5-HT3AB receptor.  Our hypothesis is that the tail current is due to 
agonism of the receptor via the orthosteric site in the presence of the orthosteric 
ligand. This is supported by the absence of a tail current and lack of Cl-indole 
competition in the presence of 5-HT for the heteromeric 5-HT3AB receptor. 
Interestingly, the peak 5-HT3AB heteromeric receptor current was potentiated by Cl-
indole. We interpret this to mean that Cl-indole may have an allosteric action via the 
A-B and B-A interfaces. The potential for allosteric action through an A-B or B-A site 
is supported by Miles et al (Miles et al., 2015) who showed that mcPBG can be both 
an agonist and allosteric modulator at the  heteromeric receptor. These observations 
are consistent with our proposal that Cl-indole forms a new class of molecule 
exhibiting both agonist and allosteric actions requiring the presence of the orthosteric 
ligand. 
The novel mechanism of action of Cl-indole at the 5-HT3 receptor may offer 
therapeutic advantages for ligands with this mechanism at LGICs. Thus for instance 
a potentiation of 5-HT3 receptor function may benefit patients with constipation-
predominant irritable bowel syndrome. Furthermore, if the novel mechanism 
translates to other members of the LGIC receptor superfamily, then such potentiation 
of GABAA receptors for example may offer benefits for the treatment of a variety of 
conditions such as anxiety. Alternatively, a potentiation of nicotinic acetylcholine 
receptors may benefit patients with cognitive decline. 
In summary, using the 5-HT3A receptor as a model, this study identifies a previously 
unknown mode of activation of LGICs. We demonstrate that Cl-indole represents a 
modulator requiring the presence of the orthosteric ligand for its action – a Cryptic 
Orthosteric Modulator. The retained physiological control via the endogenous agonist 
to reveal both actions may offer therapeutic advantages for drugs targeting LGICs 
via this mechanism.  
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 [5-HT] nM IC50 (µM) 
Cl-indole PBG 
0 >100 15±2 
10 77±12 14±1 
30 49±12 14±1 
100 27±6 15±3 
200 10±1 10±2 
 
Table 1. Ability of Cl-indole and PBG to compete for [3H]-granisetron binding to the 
orthosteric site of the 5-HT3A receptor. Data represent IC50 values for the competing 
drugs in the absence or presence of 5-HT (mean±SEM, n=4-8). 
  
 [5-HT] (nM) Cl-indole IC50 (μM) 
0 144±41 
10 306±63 
30 198±42 
100 222±40 
200 255±83 
300 210±40 
 
 
Table 2. Ability of Cl-indole to compete for [3H]-granisetron binding to the orthosteric 
site of the 5-HT3AB receptor. Data represent IC50 values for the competing drugs in the 
absence or presence of 5-HT (mean±SEM, n=5). 
 
 
 
  
  
 
 
Figure 1. Cl-indole is not a 5-HT3A receptor agonist 
Cl-indole (30 M 100 ms) did not evoke a response. However in the presence of 5-
HT (10 M, bath application), Cl-indole (30 M 100 ms) provoked an inward current. 
Representative trace, n=7.  
  
Figure 2. Cl-indole does not modulate 5-HT3A receptor desensitisation (Ai); 
Prolonged application of 5-HT (10 μM, 20 seconds) activated a large 5-HT3A 
receptor current that displayed pronounced desensitisation under control conditions 
(black trace); single recording representative of 11 recordings.The magnitude and 
kinetics of desensitisation of the current evoked by 10 M 5-HT were unaffected by 
concomitant bath application of Cl-indole (10 μM) (red trace).(Aii) Normalising 5-HT 
(10 μM) induced current to the peak response highlighted the lack of effect of Cl-
indole on receptor desensitisation. (Bi & ii) The time constants of the current decay 
in the absence (black bar) or presence (red bar) of Cl-indole (10 M). (Biii) Degree of 
receptor desensitisation in the absence (black bar) or presence (red bar) of Cl-indole 
(10 M). Data represent the mean ± SEM, n=11). 
 
 
  
 Figure 3. Cl-indole does not modulate 5-HT3A receptor recovery from 
desensitisation. (A) A single prolonged application (P1) of 5-HT (10 μM, 20 s) 
induced similar receptor desensitisation in absence (black trace) or the presence of 
Cl-indole (10 μM, red trace). After removal of the 5-HT, a second test pulse (P2) of 5-
HT (10 μM, 1 s) with a delay between 5 s and 2 minutes tested recovery from 
desensitisation; a single representative trace from 5 recordings.  Traces show an 
example recording with a 30 s interpulse interval.  (B) Fractional recovery of the 
current amplitude elicited by the second 5-HT pulse (P2/P1) was plotted against the 
inter-pulse interval in the absence (black symbols) or presence of Cl-indole (10 µM, 
red symbols); data represent the mean±SEM, n=5. 
 Figure 4. Cl-indole evokes tail currents (A) In control conditions, the current 
decayed back to baseline levels after removal of 5-HT (black trace). In contrast, 
removal of the agonist in the presence of Cl-indole (red trace) induced a tail current 
with slow activation and deactivation kinetics. The presence of the tail current was 
completely reversible upon removal of Cl-indole (grey trace); trace representative of 
13 recordings. (B) Peak tail current amplitude did not correlate with the degree of 
receptor desensitation (Bi) resulting from a 20s 5-HT application ( - 10 μM,  - 3 
μM,  - 1 μM), but correlated with 5-HT-induced current density (Bii). Data 
represent individual recordings. 
 
  
 Figure 5. Cl-indole does not modulate the current voltage relationship of the 5-
HT3A receptor current.  (A) IV curves (-120 mV – 120 mV) were constructed at the 
peak of the Cl-indole-induced tail current. (B) The current voltage relationship was 
unaltered by Cl-indole (10 M). Data represent the mean±SEM, n=6. 
  
 Figure 6. Cl-indole induced tail current amplitude is independent of 5-HT 
concentration.(A and Bi) In the presence of Cl-indole (10 µM), application of 5-HT 
evoked a concentration dependent inward current (10 μM – black trace, 1 μM – red 
trace; trace representative of 9 recordings). (A and Bii) A similar amplitude tail 
current was observed at all agonist concentrations.  (Biii) The rise time of the tail 
currents was dependent on 5-HT concentration. Bar graphs represent mean+SEM, 
n=9. 
 
  
 Figure 7. 5-Cl-indole mediated tail currents are blocked by ondansetron. (A) Selective 
orthosteric antagonist, ondansetron (10 µM, 15 s), applied one second prior to removal of 5-
HT (10 µM, 20 s), completely blocked tail currents (grey trace), which are usually seen in the 
presence of 5-Cl-indole (red trace). (B) Ondansetron (10 µM, 10 s) applied at the peak of the 
tail current, completely blocked the tail current (grey trace). Traces representative of 5 
recordings. Bar graphs represent mean+SEM, n=5. 
  
  
Figure 8. The presence of 5-HT allows Cl-indole to compete for [3H]-granisetron 
binding to the orthosteric site of the 5-HT3A receptor. Left graph: Cl-indole (up to 100 
µM) essentially does not compete for [3H]-granisetron in the absence of 5-HT, but in the 
presence of 5-HT (10 – 300 nM), there is a concentration-dependent increase in the affinity 
of Cl-indole for the [3H]-granisetron-labelled orthosteric site. Right graph: the same 
concentrations of 5-HT fail to alter the affinity of the orthosteric agonist, PBG. Data from a 
single experiment that was representative of 4-8 independent experiments (see Table 1 for 
summary of arising data). 
 
  
0
1750
3500
10
-8
10
-7
10
-6
10
-5
10
-4
d
p
m
[PBG] (M)
0
1300
2600
10
-7
10
-6
10
-5
10
-4
Cl-indole alone
Cl-indole + 5-HT (300 nM)
Cl-indole + 5-HT (200 nM)
Cl-indole + 5-HT (100 nM)
Cl-indole + 5-HT (30 nM)
Cl-indole + 5-HT (10 nM)
d
p
m
[Cl-indole] (M)
0
1300
2600
10
-7
10
-6
10
-5
10
-4
Cl-indole alone
+ 5-HT (300 nM)
2
1
3  nM)
1
d
p
m
[Cl-indole] (M)
PBG	alone	
PBG	+	5-HT	(200	nM)	
PBG	+	5-HT	(100	nM)	
PBG	+	5-HT	(30	nM)	
PBG	+	5-HT	(10	nM)	
0
1300
2600
10
-7
10
-6
10
-5
10
-4
d
p
m
[Cl-indole] (M)
0
1300
2600
10
-7
10
-6
10
-5
10
-4
Cl-indole alone
Cl-indole + 5-HT (300 nM)
Cl-indole + 5-HT (200 nM)
Cl-indole + 5-HT (100 nM)
Cl-indole + 5-HT (30 nM)
Cl-indole + 5-HT (10 nM)
d
p
m
[Cl-indole] (M)
0
1300
2600
10
-7
10
-6
10
-5
10
-4
Cl-indole alone
+ 5-HT (300 nM)
2
1
3  nM)
1
d
p
m
[Cl-indole] (M)
l 	 lone	
l 	 	5-HT	(20 	nM)	
l i l 	 	5-HT	(10 	nM)	
l-i l 	 	5-HT	(30	nM)	
l-i l 	 	5-HT	(10	nM)	
  
Figure 9. Cl-indole does not induce tail currents in heteromeric 5-HT3AB 
receptors. (A) Pressure ejection of 5-HT (10 M, 20 s, 20 psi) evoked a rapidly 
desensitising current in both control (black trace) and in the presence of 30 M Cl-
indole (red trace). Removal of 5-HT did not induce a tail current in either condition. 
(B) Cl-indole (30 M, left panel, n=5; 10 M right panel, n=6) potentiated the peak 5-
HT current amplitude. Bar graphs represent mean+SEM.  
 
 
